Ultragenyx Pharma(RARE.US)

Event Tracking

Apr2

Ultragenyx’s UX111 Gene Therapy BLA Application Accepted by FDA

12:34

Mar30

Ultragenyx Obtains FDA IND Approval for UX016

12:32

Mar12

Ultragenyx Announces Positive Results from DTX301 Phase III Trial

12:36

Feb23

FDA Accepts Ultragenyx's DTX401 Biologics License Application for Priority Review

13:30

Feb13

Ultragenyx Pharma released FY2025 earnings on February 12 After-Market EST, actual revenue USD 673 M (forecast USD 668.36 M), actual EPS USD -5.8316 (forecast USD -5.6531)

00:00

Ultragenyx Pharma released FY2025 Q4 earnings on February 12 After-Market (EST), actual revenue USD 0 (forecast USD 201.86 M), actual EPS USD 0 (forecast USD -1.1293)

00:00